TOP HEADLINES

Featured Story

Sanofi, Regeneron point to potential heart benefit in PCSK9 data dump

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some...

Novartis' LCZ696 kindles megablockbuster projections with impressive PhIII heart data

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma...

ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales

Disappointing sales of ThromboGenics' only marketed product, Jetrea, have taken their toll on the company's profits this year. To get back in the black, the Belgian company now says it's spinning out its cancer R&D activities to focus on the struggling eye drug.

Band of West Coast biotech insiders pushes oral anticoagulant to PhIII

Some well-known biopharma execs on the West Coast, including Impax Labs founder and former CEO Larry Hsu, have teamed up on a low budget, late-stage program for an oral anticoagulant.

Sanofi appoints Japan exec to lead U.S. pharma ops

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...
MORE NEWS

From Our Sister Sites

FiercePharma

Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs?

FierceMedicalDevices

The latest in a series of guidances explaining and implementing last year's Unique Device Identification final rule is "little more than a regurgitation of information contained in the rule itself, the preamble to the rule, the UDI website, and the Global Unique Device Identification (GUDID) guidance document," wrote medical device law attorney Jennifer Newberger.